Helicobacter pylori Treatment Regimens

Current Treatment Landscape

In areas with low clarithromycin resistance (<10%), traditional triple therapy (PPI + clarithromycin + amoxicillin) may still be used, but should be administered for 14 days rather than 7 days to improve eradication rates 1, 3
In areas with high clarithromycin resistance (>15-20%), bismuth-containing quadruple therapy is recommended as first-line treatment 1, 4
If bismuth quadruple therapy is unavailable, sequential therapy or non-bismuth quadruple therapy (concomitant therapy) should be considered 3, 4

High-dose PPI (twice daily) significantly increases the efficacy of triple therapy by 6-10% compared to standard doses 3, 4
Extending treatment duration from 7 to 10-14 days improves eradication success by approximately 5% 3, 4
The goal of treatment is to achieve mucosal antibiotic concentrations above the minimum inhibitory concentration (MIC) for H. pylori 5, 6

Clarithromycin resistance is the primary reason for triple therapy failure 1, 2
Global clarithromycin resistance rates have increased from 9% in 1998 to 17.6% in 2008-2009 1, 2
In regions with clarithromycin resistance >15-20%, empiric triple therapy without susceptibility testing should be abandoned 1, 2
There is cross-resistance within antibiotic families (all macrolides, all fluoroquinolones) but not between different antibiotic classes 2
When using specific antibiotics, it's essential to use the recommended compounds: clarithromycin for macrolides, tetracycline HCl (not doxycycline), and levofloxacin or moxifloxacin (not ciprofloxacin) for fluoroquinolones 2

After failure of clarithromycin-containing therapy, either bismuth-containing quadruple therapy or levofloxacin-containing triple therapy is recommended 4
Rising rates of levofloxacin resistance should be considered when selecting second-line therapy 4
After failure of second-line treatment, therapy should be guided by antimicrobial susceptibility testing whenever possible 4

Using standard triple therapy in areas with high clarithromycin resistance leads to unacceptably low eradication rates 1, 2
Inadequate dosing of PPIs reduces treatment efficacy; high-dose (twice daily) PPI should be used 3, 4
Using inappropriate antibiotic substitutes (doxycycline instead of tetracycline, ciprofloxacin instead of levofloxacin) reduces efficacy 2